Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gefitinib Versus Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance A Randomized, Multicentre, Phase II Study

Next Previous
X
Search
Trial Profile

Gefitinib Versus Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance A Randomized, Multicentre, Phase II Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gefitinib (Primary) ; Carboplatin; Pemetrexed; Rivoceranib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Qilu Pharmaceutical

    • Most Recent Events

    • 31 Jul 2020 Planned number of patients changed from 300 to 100.
    • 31 Jul 2020 Planned End Date changed from 20 Aug 2019 to 30 Dec 2021.
    • 31 Jul 2020 Planned primary completion date changed from 20 Aug 2019 to 20 Oct 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top